Erratum: USP22 promotes the G1/S phase transition by upregulating FoxM1 expression via β-catenin nuclear localization and is associated with poor prognosis in stage II pancreatic ductal adenocarcinoma (International Journal of Oncology (2014) 45 (1594-1608) DOI:10.3892/ijo.2014.2531);USP22 promotes the G1/S phase transition by upregulating FoxM1 expression via β-catenin nuclear localization and is associated with poor prognosis in stage II pancreatic ductal adenocarcinoma

International Journal of Oncology

Volumn 45, Issue 4, 2014, Pages 1594-1608

  Ning, Zhen ^a   Wang, Aman ^a   Liang, Jinxiao ^a   Xie, Yunpeng ^a   Liu, Jiwei ^a   Feng, Lu ^a   Yan, Qiu ^a   Wang, Zhongyu ^a  

^a DALIAN MEDICAL UNIVERSITY   (China)

Author keywords

Cell cycle; Forkhead box M1; Pancreatic ductal adenocarcinoma; Prognosis; Ubiquitin specific protease 22; Wnt catenin

Indexed keywords

BETA CATENIN; CHOLECYSTOKININ OCTAPEPTIDE; DEUBIQUITINASE; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR FOXM1; UBIQUITIN SPECIFIC PROTEASE 22; UNCLASSIFIED DRUG; CTNNB1 PROTEIN, HUMAN; FORKHEAD TRANSCRIPTION FACTOR; FOXM1 PROTEIN, HUMAN; THIOL ESTER HYDROLASE; USP22 PROTEIN, HUMAN;

ADULT; ARTICLE; CANCER GROWTH; CANCER PROGNOSIS; CANCER SIZE; CANCER STAGING; CANCER SURVIVAL; CANCER TISSUE; CARCINOMA CELL; CELL CYCLE S PHASE; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL VIABILITY; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; DOWN REGULATION; FEMALE; G1 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPH NODE METASTASIS; MALE; NUCLEAR LOCALIZATION SIGNAL; PANCREAS ADENOCARCINOMA; PANCREAS RESECTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION; WNT SIGNALING PATHWAY; AGED; CELL NUCLEUS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MIDDLE AGED; PANCREAS CARCINOMA; PANCREAS TUMOR; PATHOLOGY; PROGNOSIS; SURVIVAL; TUMOR CELL LINE;

AGED; BETA CATENIN; CARCINOMA, PANCREATIC DUCTAL; CELL LINE, TUMOR; CELL NUCLEUS; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; G1 PHASE CELL CYCLE CHECKPOINTS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; PROGNOSIS; SURVIVAL ANALYSIS; THIOLESTER HYDROLASES;

EID: 84907459383     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2019.4871     Document Type: Erratum

References (70)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin 61: 69-90, 2011.
2. Hidalgo M: Pancreatic cancer. N Engl J Med 362: 1605-1617, 2010.
3. Singh P, Srinivasan R and Wig JD: Major molecular markers in pancreatic ductal adenocarcinoma and their roles in screening, diagnosis, prognosis, and treatment. Pancreas 40: 644-652, 2011.
4. Lee HJ, Kim MS, Shin JM, Park TJ, Chung HM and Baek KH: The expression patterns of deubiquitinating enzymes, USP22 and Usp22. Gene Expr Patterns 6: 277-284, 2006.
5. Zhang XY, Varthi M and Sykes SM, et al: The putative cancer stem cell marker USP22 is a subunit of the human SAGA complex required for activated transcription and cell-cycle progression. Mol Cell 29: 102-111, 2008.
6. Lin Z, Yang H and Kong Q, et al: USP22 antagonizes p53 transcriptional activation by deubiquitinating Sirt1 to suppress cell apoptosis and is required for mouse embryonic development. Mol Cell 46: 484-494, 2012.
7. Atanassov BS, Evrard YA and Multani AS, et al: Gcn5 and SAGA regulate shelterin protein turnover and telomere maintenance. Mol Cell 35: 352-364, 2009.
8. Xu H, Liu YL, Yang YM and Dong XS: Knock-down of ubiq-uitin- specific protease 22 by micro-RNA interference inhibits colorectal cancer growth. Int J Colorectal Dis 27: 21-30, 2012.
9. Lv L, Xiao XY, Gu ZH, Zeng FQ, Huang LQ and Jiang GS: Silencing USP22 by asymmetric structure of interfering RNA inhibits proliferation and induces cell cycle arrest in bladder cancer cells. Mol Cell Biochem 346: 11-21, 2011.
10. Ling SB, Sun DG, Tang B, et al: Knock-down of USP22 by small interfering RNA interference inhibits HepG2 cell proliferation and induces cell cycle arrest. Cell Mol Biol (Noisy-le-grand) 58: L1803-L1808, 2012.
11. Glinsky GV: Genomic models of metastatic cancer: functional analysis of death-from-cancer signature genes reveals aneuploid, anoikis-resistant, metastasis-enabling phenotype with altered cell cycle control and activated Polycomb Group (PcG) protein chromatin silencing pathway. Cell Cycle 5: 1208-1216, 2006.
12. Glinsky GV, Berezovska O and Glinskii AB: Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer. J Clin Invest 115: 1503-1521, 2005. (Pubitemid 40814659)
13. Jackson BC, Carpenter C, Nebert DW and Vasiliou V: Update of human and mouse forkhead box (FOX) gene families. Hum Genomics 4: 345-352, 2010.
14. Laoukili J, Kooistra MR and Bras A, et al: FoxM1 is required for execution of the mitotic programme and chromosome stability. Nat Cell Biol 7: 126-136, 2005. (Pubitemid 40268127)
15. Wierstra I and Alves J: FOXM1, a typical proliferation-associated transcription factor. Biol Chem 388: 1257-1274, 2007. (Pubitemid 350135573)
16. Luscher-Firzlaff JM, Lilischkis R and Luscher B: Regulation of the transcription factor FOXM1c by Cyclin E/CDK2. Febs Lett 580: 1716-1722, 2006.
17. Major ML, Lepe R and Costa RH: Forkhead box M1B transcriptional activity requires binding of Cdk-cyclin complexes for phosphorylation-dependent recruitment of p300/CBP coactivators. Mol Cell Biol 24: 2649-2661, 2004. (Pubitemid 38381258)
18. Wang X, Hung NJ and Costa RH: Earlier expression of the transcription factor HFH-11B diminishes induction of p21(CIP1/WAF1) levels and accelerates mouse hepatocyte entry into S-phase following carbon tetrachloride liver injury. Hepatology 33: 1404-1414, 2001. (Pubitemid 32496977)
19. Wang X, Krupczak-Hollis K, Tan Y, Dennewitz MB, Adami GR and Costa RH: Increased hepatic Forkhead Box M1B (FoxM1B) levels in old-aged mice stimulated liver regeneration through diminished p27Kip1 protein levels and increased Cdc25B expression. J Biol Chem 277: 44310-44316, 2002. (Pubitemid 36157865)
20. Laoukili J, Stahl M and Medema RH: FoxM1: at the crossroads of ageing and cancer. Biochim Biophys Acta 1775: 92-102, 2007. (Pubitemid 44881197)
21. Wang Z, Ahmad A, Banerjee S, et al: FoxM1 is a novel target of a natural agent in pancreatic cancer. Pharm Res 27: 1159-1168, 2010.
22. Wang Z, Banerjee S, Kong D, Li Y and Sarkar FH: Down-regulation of Forkhead Box M1 transcription factor leads to the inhibition of invasion and angiogenesis of pancreatic cancer cells. Cancer Res 67: 8293-8300, 2007. (Pubitemid 47395167)
23. Bao B, Wang Z, Ali S, et al: Over-expression of FoxM1 leads to epithelial-mesenchymal transition and cancer stem cell phenotype in pancreatic cancer cells. J Cell Biochem 112: 2296-2306, 2011.
24. Li X, Qiu W, Liu B, et al: Forkhead box transcription factor 1 expression in gastric cancer: FOXM1 is a poor prognostic factor and mediates resistance to docetaxel. J Transl Med 11: 204, 2013.
25. Wang Y, Wen L, Zhao SH, Ai ZH, Guo JZ and Liu WC: FoxM1 expression is significantly associated with cisplatin-based chemotherapy resistance and poor prognosis in advanced non-small cell lung cancer patients. Lung Cancer 79: 173-179, 2013.
26. Xia JT, Wang H, Liang LJ, et al: Overexpression of FOXM1 is associated with poor prognosis and clinicopathologic stage of pancreatic ductal adenocarcinoma. Pancreas 41: 629-635, 2012.
27. Huang H and He X: Wnt/beta-catenin signaling: new (and old) players and new insights. Curr Opin Cell Biol 20: 119-125, 2008.
28. Karayiannakis AJ, Syrigos KN, Polychronidis A and Simopoulos C: Expression patterns of alpha-, beta- and gamma-catenin in pancreatic cancer: correlation with E-cadherin expression, pathological features and prognosis. Anticancer Res 21: 4127-4134, 2001. (Pubitemid 34229299)
29. Lowy AM, Fenoglio-Preiser C, Kim OJ, et al: Dysregulation of beta-catenin expression correlates with tumor differentiation in pancreatic duct adenocarcinoma. Ann Surg Oncol 10: 284-290, 2003. (Pubitemid 40486962)
30. Pasca DMM, Biankin AV, Heiser PW, et al: Common activation of canonical Wnt signaling in pancreatic adenocarcinoma. PLoS One 2: e1155, 2007.
31. Zhang N, Wei P, Gong A, et al: FoxM1 promotes beta-catenin nuclear localization and controls Wnt target-gene expression and glioma tumorigenesis. Cancer Cell 20: 427-442, 2011.
32. Deer EL, Gonzalez-Hernandez J, Coursen JD, et al: Phenotype and genotype of pancreatic cancer cell lines. Pancreas 39: 425-435, 2010.
33. Yang DD, Cui BB, Sun LY, et al: The co-expression of USP22 and BMI-1 may promote cancer progression and predict therapy failure in gastric carcinoma. Cell Biochem Biophys 61: 703-710, 2011.
34. Wang H, Li YP, Chen JH, et al: Prognostic significance of USP22 as an oncogene in papillary thyroid carcinoma. Tumour Biol 34: 1635-1639, 2013.
35. Zhang Y, Yao L, Zhang X, et al: Elevated expression of USP22 in correlation with poor prognosis in patients with invasive breast cancer. J Cancer Res Clin Oncol 137: 1245-1253, 2011.
36. Hu J, Liu YL, Piao SL, Yang DD, Yang YM and Cai L: Expression patterns of USP22 and potential targets BMI-1, PTEN, p-AKT in non-small-cell lung cancer. Lung Cancer 77: 593-599, 2012.
37. Li J, Wang Z and Li Y: USP22 nuclear expression is significantly associated with progression and unfavorable clinical outcome in human esophageal squamous cell carcinoma. J Cancer Res Clin Oncol 138: 1291-1297, 2012.
38. Liu Y, Yang Y, Xu H and Dong X: Implication of USP22 in the regulation of BMI-1, c-Myc, p16INK4a, p14ARF, and cyclin D2 expression in primary colorectal carcinomas. Diagn Mol Pathol 19: 194-200, 2010.
39. Nagy Z, Riss A, Romier C, et al: The human SPT20-containing SAGA complex plays a direct role in the regulation of endoplasmic reticulum stress-induced genes. Mol Cell Biol 29: 1649-1660, 2009.
40. Nagy Z and Tora L: Distinct GCN5/PCAF-containing complexes function as co-activators and are involved in transcription factor and global histone acetylation. Oncogene 26: 5341-5357, 2007. (Pubitemid 47255920)
41. Zhang XY, Pfeiffer HK, Thorne AW and McMahon SB: USP22, an hSAGA subunit and potential cancer stem cell marker, reverses the polycomb-catalyzed ubiquitylation of histone H2A. Cell Cycle 7: 1522-1524, 2008. (Pubitemid 351881314)
42. Atanassov BS and Dent SY: USP22 regulates cell proliferation by deubiquitinating the transcriptional regulator FBP1. EMBO Rep 12: 924-930, 2011.
43. Fu Z, Malureanu L, Huang J, et al: Plk1-dependent phosphorylation of FoxM1 regulates a transcriptional programme required for mitotic progression. Nat Cell Biol 10: 1076-1082, 2008.
44. Anders L, Ke N, Hydbring P, et al: A systematic screen for CDK4/6 substrates links FOXM1 phosphorylation to senescence suppression in cancer cells. Cancer Cell 20: 620-634, 2011.
45. Wang X, Bhattacharyya D, Dennewitz MB, et al: Rapid hepatocyte nuclear translocation of the Forkhead Box M1B (FoxM1B) transcription factor caused a transient increase in size of regenerating transgenic hepatocytes. Gene Expr 11: 149-162, 2003. (Pubitemid 37516648)
46. Wang IC, Chen YJ, Hughes D, et al: Forkhead box M1 regulates the transcriptional network of genes essential for mitotic progression and genes encoding the SCF (Skp2-Cks1) ubiquitin ligase. Mol Cell Biol 25: 10875-10894, 2005. (Pubitemid 41747132)
47. Allende-Vega N and Saville MK: Targeting the ubiquitinproteasome system to activate wild-type p53 for cancer therapy. Semin Cancer Biol 20: 29-39, 2010.
48. Clurman BE, Sheaff RJ, Thress K, Groudine M and Roberts JM: Turnover of cyclin E by the ubiquitin-proteasome pathway is regulated by cdk2 binding and cyclin phosphorylation. Genes Dev 10: 1979-1990, 1996. (Pubitemid 26346107)
49. Bae Y, Choi D, Rhim H and Kang S: Hip2 interacts with cyclin B1 and promotes its degradation through the ubiquitin proteasome pathway. FEBS Lett 584: 4505-4510, 2010.
50. Pagano M, Tam SW, Theodoras AM, et al: Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science 269: 682-685, 1995.
51. Ding GX, Liu J, Feng CC, Jiang HW, Xu JF and Ding Q: Slug regulates Cyclin D1 expression by ubiquitin-proteasome pathway in prostate cancer cells. Panminerva Med 54: 219-223, 2012.
52. Mandal S, Freije WA, Guptan P and Banerjee U: Metabolic control of G1-S transition: cyclin E degradation by p53-induced activation of the ubiquitin-proteasome system. J Cell Biol 188: 473-479, 2010.
53. Wang IC, Chen YJ, Hughes DE, et al: FoxM1 regulates transcription of JNK1 to promote the G1/S transition and tumor cell invasiveness. J Biol Chem 283: 20770-20778, 2008.
54. Nakamura S, Hirano I, Okinaka K, et al: The FOXM1 transcriptional factor promotes the proliferation of leukemia cells through modulation of cell cycle progression in acute myeloid leukemia. Carcinogenesis 31: 2012-2021, 2010.
55. Priller M, Poschl J, Abrao L, et al: Expression of FoxM1 is required for the proliferation of medulloblastoma cells and indicates worse survival of patients. Clin Cancer Res 17: 6791-6801, 2011.
56. He SY, Shen HW, Xu L, et al: FOXM1 promotes tumor cell invasion and correlates with poor prognosis in early-stage cervical cancer. Gynecol Oncol 127: 601-610, 2012.
57. Wierstra I and Alves J: FOXM1c transactivates the human c-myc promoter directly via the two TATA boxes P1 and P2. FEBS J 273: 4645-4667, 2006. (Pubitemid 44506907)
58. De Boer VC, de Goffau MC, Arts IC, Hollman PC and Keijer J: SIRT1 stimulation by polyphenols is affected by their stability and metabolism. Mech Ageing Dev 127: 618-627, 2006. (Pubitemid 43729534)
59. Zhu GY, Shi BZ and Li Y: FoxM1 regulates Sirt1 expression in glioma cells. Eur Rev Med Pharmacol Sci 18: 205-211, 2014.
60. Jiang L, Li J and Song L: Bmi-1, stem cells and cancer. Acta Biochim Biophys Sin (Shanghai) 41: 527-534, 2009.
61. Liu YL, Jiang SX, Yang YM, Xu H, Liu JL and Wang XS: USP22 acts as an oncogene by the activation of BMI-1-mediated INK4a/ARF pathway and Akt pathway. Cell Biochem Biophys 62: 229-235, 2012.
62. Li SK, Smith DK, Leung WY, et al: FoxM1c counteracts oxidative stress-induced senescence and stimulates Bmi-1 expression. J Biol Chem 283: 16545-16553, 2008.
63. Katoh M and Katoh M: WNT signaling pathway and stem cell signaling network. Clin Cancer Res 13: 4042-4045, 2007. (Pubitemid 47105963)
64. Heiser PW, Lau J, Taketo MM, Herrera PL and Hebrok M: Stabilization of beta-catenin impacts pancreas growth. Development 133: 2023-2032, 2006. (Pubitemid 43881267)
65. Rulifson IC, Karnik SK, Heiser PW, et al: Wnt signaling regulates pancreatic beta cell proliferation. Proc Natl Acad Sci USA 104: 6247-6252, 2007. (Pubitemid 47186080)
66. Heiser PW, Cano DA, Landsman L, et al: Stabilization of beta-catenin induces pancreas tumor formation. Gastroenterology 135: 1288-1300, 2008.
67. Zhang Y, Morris JT, Yan W, et al: Canonical wnt signaling is required for pancreatic carcinogenesis. Cancer Res 73: 4909-4922, 2013.
68. Ripka S, Konig A, Buchholz M, et al: WNT5A - target of CUTL1 and potent modulator of tumor cell migration and invasion in pancreatic cancer. Carcinogenesis 28: 1178-1187, 2007. (Pubitemid 47062676)
69. Griesmann H, Ripka S, Pralle M, et al: WNT5A-NFAT signaling mediates resistance to apoptosis in pancreatic cancer. Neoplasia 15: 11-22, 2013.
70. Bowman A and Nusse R: Location, location, location: FoxM1 mediates beta-catenin nuclear translocation and promotes glioma tumorigenesis. Cancer Cell 20: 415-416, 2011.